Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/S ratio high or low?
The P/S ratio of 1.87 is 38% below its estimated 1-year average of 3.04, near the low end of its estimated 1-year range (1.87–5.24).
As of 2026-10-06T19:46:44.222Z.
Calculation as of: 2026-10-06T19:46:44.222Z.
Quote observation: 2026-10-06T19:45:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1719e487edf1987d8b1f0a43ac2cfa0d2aa61af237e007c9f807b404ec58ada8
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
1.87
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.27
median of 579 covered companies
CURRENT VS SECTOR MEDIAN
-56.21%
vs the sector median at left
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | $13.30M | 1.87 | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.48M | 108.46 | 130.06 | 643.92 | 552.45 |
| IN8bio, Inc. (INAB)vs › | $13.12M | N/A | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.85M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.77M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.57M | 0.34 | 0.98 | 1.40 | 2.22 |
| Sintx Technologies, Inc. (SINT)vs › | $13.99M | 10.13 | 7.29 | 6.12 | 1270.11 |
| Vyome Holdings, Inc. (HIND)vs › | $14.25M | 109.83 | 20.09 | 7.30 | 5.50 |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.18M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.47M | 9.13 | 21.58 | 247.97 | 174.73 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-23 |
| Q1 FY2026Period ended 2025-12-31 | $3,944,111 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-13 |
| Q2 FY2026Period ended 2026-03-31 | $1,667,298 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-15 |
| Q3 FY2026Period ended 2026-06-30 | $1,493,788 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $7,105,197 |
Current P/S: $13,300,770 market capitalization ÷ $7,105,197 TTM revenue = 1.87x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T19:45:03.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
At 1.87, P/S is below its estimated 1-year median — higher than 0% of readings in its estimated 1-year history.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
estimated 1-year low
1.92
median
2.46
estimated 1-year high
5.24
P/S Ratio
1.87
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2026-10-05 | 1.92 |
| 2026-10-02 | 1.96 |
| 2026-10-01 | 1.99 |
| 2026-09-30 | 1.96 |
| 2026-09-29 | 2.04 |
| 2026-09-28 | 2.02 |
| 2026-09-25 | 2.13 |
| 2026-09-24 | 2.10 |
| 2026-09-23 | 2.09 |
| 2026-09-22 | 2.20 |
| 2026-09-21 | 2.12 |
| 2026-09-18 | 2.21 |
| 2026-09-17 | 2.17 |
| 2026-09-16 | 2.06 |
| 2026-09-15 | 2.06 |
| 2026-09-14 | 2.11 |
| 2026-09-11 | 2.14 |
| 2026-09-10 | 2.16 |
| 2026-09-09 | 2.14 |
| 2026-09-08 | 2.21 |
| 2026-09-04 | 2.16 |
| 2026-09-03 | 2.22 |
| 2026-09-02 | 2.13 |
| 2026-09-01 | 2.10 |
| 2026-08-31 | 2.14 |
| 2026-08-28 | 2.22 |
| 2026-08-27 | 2.32 |
| 2026-08-26 | 2.13 |
| 2026-08-25 | 2.22 |
| 2026-08-24 | 2.12 |
| 2026-08-21 | 2.21 |
| 2026-08-20 | 2.21 |
| 2026-08-19 | 2.35 |
| 2026-08-18 | 2.11 |
| 2026-08-17 | 2.07 |
| 2026-08-14 | 3.01 |
| 2026-08-13 | 2.93 |
| 2026-08-12 | 3.05 |
| 2026-08-11 | 2.87 |
| 2026-08-10 | 2.70 |
| 2026-08-07 | 2.72 |
| 2026-08-06 | 2.56 |
| 2026-08-05 | 3.11 |
| 2026-08-04 | 2.48 |
| 2026-08-03 | 2.38 |
| 2026-07-31 | 2.27 |
| 2026-07-30 | 2.52 |
| 2026-07-29 | 2.27 |
| 2026-07-28 | 1.99 |
| 2026-07-27 | 2.06 |
| 2026-07-24 | 2.07 |
| 2026-07-23 | 2.12 |
| 2026-07-22 | 2.24 |
| 2026-07-21 | 2.18 |
| 2026-07-20 | 1.92 |
| 2026-07-17 | 1.98 |
| 2026-07-16 | 2.04 |
| 2026-07-15 | 2.12 |
| 2026-07-14 | 2.12 |
| 2026-07-13 | 2.15 |
| 2026-07-10 | 2.32 |
| 2026-07-09 | 2.24 |
| 2026-07-08 | 2.22 |
| 2026-07-07 | 2.33 |
| 2026-07-06 | 2.42 |
| 2026-07-02 | 2.29 |
| 2026-07-01 | 2.43 |
| 2026-06-30 | 2.41 |
| 2026-06-29 | 2.31 |
| 2026-06-26 | 2.15 |
| 2026-06-25 | 2.17 |
| 2026-06-24 | 2.27 |
| 2026-06-23 | 2.23 |
| 2026-06-22 | 2.27 |
| 2026-06-18 | 2.18 |
| 2026-06-17 | 2.15 |
| 2026-06-16 | 2.16 |
| 2026-06-15 | 2.15 |
| 2026-06-12 | 2.15 |
| 2026-06-11 | 2.28 |
| 2026-06-10 | 2.20 |
| 2026-06-09 | 2.22 |
| 2026-06-08 | 2.35 |
| 2026-06-05 | 2.23 |
| 2026-06-04 | 2.35 |
| 2026-06-03 | 2.31 |
| 2026-06-02 | 2.41 |
| 2026-06-01 | 2.53 |
| 2026-05-29 | 2.61 |
| 2026-05-28 | 2.60 |
| 2026-05-27 | 2.75 |
| 2026-05-26 | 2.78 |
| 2026-05-22 | 2.80 |
| 2026-05-21 | 2.68 |
| 2026-05-20 | 2.31 |
| 2026-05-19 | 2.21 |
| 2026-05-18 | 2.10 |
| 2026-05-15 | 3.82 |
| 2026-05-14 | 3.92 |
| 2026-05-13 | 3.54 |
| 2026-05-12 | 3.34 |
| 2026-05-11 | 3.48 |
| 2026-05-08 | 3.49 |
| 2026-05-07 | 3.56 |
| 2026-05-06 | 3.63 |
| 2026-05-05 | 3.74 |
| 2026-05-04 | 3.87 |
| 2026-05-01 | 3.81 |
| 2026-04-30 | 3.79 |
| 2026-04-29 | 3.24 |
| 2026-04-28 | 3.54 |
| 2026-04-27 | 3.77 |
| 2026-04-24 | 4.20 |
| 2026-04-23 | 5.08 |
| 2026-04-22 | 4.69 |
| 2026-04-21 | 4.60 |
| 2026-04-20 | 4.76 |
| 2026-04-17 | 4.68 |
| 2026-04-16 | 4.66 |
| 2026-04-15 | 4.67 |
| 2026-04-14 | 4.49 |
| 2026-04-13 | 4.44 |
| 2026-04-10 | 4.39 |
| 2026-04-09 | 4.59 |
| 2026-04-08 | 4.52 |
| 2026-04-07 | 4.30 |
| 2026-04-06 | 4.69 |
| 2026-04-02 | 4.66 |
| 2026-04-01 | 4.59 |
| 2026-03-31 | 4.90 |
| 2026-03-30 | 3.71 |
| 2026-03-27 | 3.92 |
| 2026-03-26 | 3.78 |
| 2026-03-25 | 3.92 |
| 2026-03-24 | 3.87 |
| 2026-03-23 | 4.09 |
| 2026-03-20 | 4.20 |
| 2026-03-19 | 4.43 |
| 2026-03-18 | 4.50 |
| 2026-03-17 | 4.42 |
| 2026-03-16 | 4.80 |
| 2026-03-13 | 5.24 |
| 2026-03-12 | 4.73 |
| 2026-03-11 | 4.96 |
| 2026-03-10 | 5.07 |
| 2026-03-09 | 4.57 |
| 2026-03-06 | 4.55 |
| 2026-03-05 | 5.17 |
| 2026-03-04 | 4.45 |
| 2026-03-03 | 4.03 |
| 2026-03-02 | 3.94 |
| 2026-02-27 | 4.03 |
| 2026-02-26 | 4.11 |
| 2026-02-25 | 4.08 |
| 2026-02-24 | 4.09 |
| 2026-02-23 | 3.63 |
| 2026-02-20 | 3.86 |
| 2026-02-19 | 3.77 |
| 2026-02-18 | 3.91 |
| 2026-02-17 | 4.04 |
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.